CTOR Stock Risk & Deep Value Analysis
Citius Oncology Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
The Bottom Line on CTOR
We analyzed Citius Oncology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CTOR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈CTOR Performance Overview3yr weekly
Unlock CTOR Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
CTOR Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Citius Oncology Inc (CTOR)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market Cap Category
small
Market Cap
$149.49M
CTOR Deep Value Analysis
CTOR Red Flags & Warning Signs
Premium- ⚠
Mino-Lok Phase 3 trial failure or unfavorable safety/efficacy results
- ⚠
Continued slower-than-expected OMTIBU commercialization and associated cash burn
- ⚠
Requirement for significant dilutive financing rounds
- ⚠
Regulatory delays or outright rejection for pipeline assets
Unlock CTOR Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
CTOR Financial Health Metrics
Market Cap
$149.49M
CTOR Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat is primarily built on intellectual property protection for its drug candidates and the market exclusivity granted by orphan drug status for OMTIBU. Its durability hinges on successful clinical development and FDA approval, which would provide patent protection for 10-15 years post-approval. However, this moat is inherently fragile due to binary clinical trial risks.
CTOR Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
CTOR Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated mid-May 2026)
- •Updates on OMTIBU commercialization and sales trajectory
- •Mino-Lok Phase 3 trial enrollment completion update
Medium-Term (6-18 months)
- •Mino-Lok Phase 3 primary endpoint data readout (estimated late 2026 / early 2027)
- •Potential strategic partnership or licensing deal for Mino-Lok
- •Initiation of additional clinical studies for OMTIBU or other pipeline assets
Long-Term (18+ months)
- •Mino-Lok New Drug Application (NDA) submission and potential FDA approval (2027-2028)
- •Significant market penetration and revenue ramp for Mino-Lok post-approval
- •Expansion of OMTIBU into broader indications or geographies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
CTOR Bull Case: What Could Go Right
- ✓
Positive Phase 3 trial data readout for Mino-Lok (primary endpoint)
- ✓
Acceleration in OMTIBU sales growth and improved cash runway
- ✓
Announcement of a strategic partnership for pipeline assets (especially Mino-Lok)
- ✓
Dilution events or significant changes in cash position
Bull Case Analysis
See what could go right with Premium
Never miss a move on CTOR
Create a free account to set price alerts and get notified on Telegram when CTOR hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Citius Oncology Inc (CTOR)?
As of March 21, 2026, Citius Oncology Inc has a DVR Score of 6.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Citius Oncology Inc?
Citius Oncology Inc's market capitalization is approximately $149.5M. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Citius Oncology Inc use?
CTOR is the ticker symbol for Citius Oncology Inc. The company trades on the NCM.
What is the risk level for CTOR stock?
Our analysis rates Citius Oncology Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the CTOR DVR analysis updated?
Our AI-powered analysis of Citius Oncology Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.